Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone in Hormone-Refractory Metastatic Breast Cancer
NCT00379197Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2006
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naltrexone in breast cancer, sponsored by Masonic Cancer Center. Primary endpoint: Disease Response at 4 weeks. Started Jul 2006; status: terminated.
02
Drugs
naltrexone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00379197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00379197.